This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
From 2 to 4 May 2023, two ECDC experts in epidemiology and health informatics participated in the second consultative workshop for the establishment of the African Epidemic Service programme held at the Institut Pasteur Du Maroc in Casablanca, Morocco.
Since the previous update on 11 April 2023, and as of 3 May 2023, no new MERS-CoV cases and no
related deaths have been reported by health authorities worldwide or by the World Health Organization (WHO).
Since the previous update on 11 April 2023, and as of 3 May 2023, no new MERS-CoV cases and no
related deaths have been reported by health authorities worldwide or by the World Health Organization (WHO).
ECDC presents lessons learned from the response of Europe’s public health sector to the pandemic and highlights follow up actions addressing relevant issues which could improve Europe’s pandemic preparedness.
This document aims to collate and present the lessons identified from the public health stakeholders who responded to the COVID-19 pandemic. It is intended to serve as input for countries revising their pandemic or emergency preparedness plans.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing below 10% positivity in week 16/2023.